ADVFN US – Market Content Editor
-

CoreWeave shares jump after $6.3 billion cloud capacity pact with NVIDIA
CoreWeave (NASDAQ:CRWV) saw its stock rise 9% Monday morning following news of a major cloud computing agreement with NVIDIA Corporation (NASDAQ:NVDA). In a filing with the SEC, CoreWeave revealed that on September 9, 2025, it executed a new order form under its existing Master Services Agreement with NVIDIA. Valued at $6.3 billion, the deal allows…
-

Trump announces TikTok agreement, shaking U.S. social media stocks
Shares of U.S. social media companies reacted on Monday after President Donald Trump announced that a deal regarding TikTok had been reached. Trump shared the news on Truth Social, saying: “The big Trade Meeting in Europe between The United States of America, and China, has gone VERY WELL! It will be concluding shortly. A deal…
-

ECD Automotive Design shares plummet after 1-for-40 reverse split
ECD Automotive Design Inc. (NASDAQ:ECDA) shares fell 33.7% in premarket trading on Monday following the company’s announcement of a 1-for-40 reverse stock split. The reverse split, set to take effect at the market open on September 18, 2025, is designed to increase the stock’s per-share price to comply with Nasdaq’s $1.00 minimum bid requirement for…
-

Hesai shares rise after $40M robotaxi lidar deal expansion
Hesai Group (NASDAQ:HSAI) shares climbed 4.4% in premarket trading on Monday after the lidar technology firm announced an expanded production agreement with a leading U.S.-based robotaxi operator, now valued at over $40 million. The contract covers lidar deliveries through the end of 2026, with Hesai designated as the exclusive provider of both long-range and short-range…
-

Helius Medical stock surges 220% after pivot to SOL-backed treasury strategy
Helius Medical Technologies Inc (NASDAQ:HSDT) shares jumped 220% in premarket trading on Monday following the announcement of a strategic shift to operate as a Solana blockchain-focused treasury vehicle. The company has launched an oversubscribed private investment in public equity (PIPE) offering, potentially raising over $1.25 billion. The PIPE itself accounts for more than $500 million…
-

Check-Cap stock surges on merger deal with MBody AI
Check-Cap Ltd. (NASDAQ:CHEK) shares jumped 360% in premarket trading on Monday after the company revealed it had entered a definitive merger agreement with MBody AI. The deal will establish a combined entity focused on embodied AI for the autonomous workforce, while Check-Cap’s existing operations will continue their R&D activities within the new organization. Under the…
-

Hyperscale Data shares surge after unveiling $100M Bitcoin treasury plan
Hyperscale Data, Inc. (AMEX:GPUS) saw its stock skyrocket 94% in premarket trading following the company’s announcement of a $100 million Bitcoin treasury strategy. The initiative is part of its transformation into a pure-play artificial intelligence data center and digital asset company. The strategy will be partially funded by proceeds from the sale of the company’s…
-

aTyr Pharma shares plunge after Phase 3 trial misses primary goal
aTyr Pharma (NASDAQ:ATYR) saw its stock tumble 80% following the announcement that its Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis did not meet the primary endpoint. The study’s main objective—change from baseline in mean daily oral corticosteroid dose at week 48—was not achieved. Patients receiving 5.0 mg/kg efzofitimod reduced their dose to an…
-

Ryan Specialty Holdings executive chairman buys $14.3M in shares
Patrick G. Ryan, Executive Chairman of Ryan Specialty Holdings (NYSE:RYAN), purchased 276,634 shares of Class A Common Stock on September 12, 2025. The shares were acquired at a weighted average price of $51.8384, totaling approximately $14,340,263. The timing of the purchase is notable as the stock has been trading near its 52-week low of $50.08,…
-

Novo Nordisk shares climb as EU approves heart benefit label for Rybelsus
Shares of Novo Nordisk A/S (NYSE:NVO) gained 2.8% in premarket trading on Monday after the European Medicines Agency (EMA) authorized an update to the Rybelsus label, highlighting cardiovascular benefits for adults with type 2 diabetes. The revised labeling for oral semaglutide (Rybelsus) is based on findings from the SOUL clinical trial, which demonstrated that the…